Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
2.040
+0.040 (2.00%)
May 19, 2025, 10:55 AM - Market open
Cyclacel Pharmaceuticals Revenue
Cyclacel Pharmaceuticals had revenue of $14.00K in the twelve months ending March 31, 2025, down -96.88% year-over-year. In the year 2024, Cyclacel Pharmaceuticals had annual revenue of $43.00K, down -89.76%.
Revenue (ttm)
$14.00K
Revenue Growth
-96.88%
P/S Ratio
1,869.73
Revenue / Employee
$1,167
Employees
12
Market Cap
26.44M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CYCC News
- 4 days ago - CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE - GlobeNewsWire
- 12 days ago - CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT - GlobeNewsWire
- 13 days ago - CYCLACEL PHARMACEUTICALS, INC. ANNOUNCES EXECUTION OF SHARE EXCHANGE AGREEMENT TO MAKE FITTERS SDN. - GlobeNewsWire
- 6 weeks ago - Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire
- 2 months ago - Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - GlobeNewsWire
- 4 months ago - Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - GlobeNewsWire
- 5 months ago - Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs - GlobeNewsWire